Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma
Authors
- Enrico Derenzini (ORCID: https://orcid.org/0000-0002-7154-8140)
- Alessandro Davini (ORCID: https://orcid.org/0009-0004-8504-3604)
- Anna Vanazzi (ORCID: https://orcid.org/0000-0002-2977-4208)
- Federica Melle (ORCID: https://orcid.org/0000-0002-5541-2673)
- Giovanna Motta (ORCID: https://orcid.org/0000-0001-5593-5397)
- Roberto Chiarle (ORCID: https://orcid.org/0000-0003-1564-8531)
- Marta Castelli (ORCID: https://orcid.org/0000-0003-4712-8389)
- Paulina Maria Nierychlewska
- Maria Chiara Quattrocchi
- Marcello Del Corvo (ORCID: https://orcid.org/0000-0002-8039-4155)
- Alessio Maria Edoardo Maraglino (ORCID: https://orcid.org/0000-0002-6515-6263)
- Valentina Tabanelli (ORCID: https://orcid.org/0000-0002-4142-2248)
- Corrado Tarella (ORCID: https://orcid.org/0000-0003-1473-6046)
- Angelica Calleri
- Maria Rosaria Sapienza (ORCID: https://orcid.org/0000-0002-1078-2128)
- Stefano Pileri
- Ginevra Lolli
Institutions
- Boston Children's Hospital (US)
- University of Milan (IT)
- Azienda USL di Bologna (IT)
- University of Turin (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- eJHaem
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/jha2.1103
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Associazione Italiana per la Ricerca sul Cancro